Food and Drug
Administration
Nonprescription Drugs Advisory Committee
September 25, 2006
FDA
Briefing Information
Disclaimer
Portions of this document have been determined
to be exempt from disclosure under the Freedom of Information
Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as white space on the
screen or on the printed page.
Tab
1. Executive Summary
Tab 2. OTC Labeling
Rule
21
CFR Subpart C.
Tab 3.
Bibliography